
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
Key Takeaways
- FDA approval positions pimicotinib as the third US CSF-1R inhibitor for TGCT, alongside pexidartinib (boxed hepatotoxicity/REMS) and vimseltinib.
- MANEUVER randomized 94 anti–CSF-1/CSF-1R–naïve patients 2:1 to pimicotinib 50 mg daily versus placebo for 24 weeks, requiring measurable disease ≥2 cm.
Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.
The FDA has approved pimicotinib (Pimjetmi; EMD Serono), an oral colony-stimulating factor 1 receptor (CSF-1R) inhibitor taken once a day, for adults with symptomatic
The approval was based on the phase 3 MANEUVER trial (
A rare tumor that arises in or around the joints and can invade nearby tissue, TGCT tends to affect otherwise healthy younger people, causing pain and loss of mobility that worsen over time.2 A Dutch nationwide study estimated the worldwide incidence of diffuse-type TGCT at 4 per million person-years, with higher rates for localized forms.3
“TGCT can profoundly affect patients’ daily lives through persistent pain, swelling, and loss of joint function,” Sydney Stern, PhD, MS, of TGCT Support, a Program of the Life Raft Group, said in a news release.2
A Third CSF-1R Inhibitor for TGCT
Pimicotinib follows pexidartinib (Turalio; Daiichi Sankyo), approved in 2019, and vimseltinib (Romvimza; Deciphera Pharmaceuticals), approved in February 2025, as the third CSF-1R inhibitor available for TGCT in the US.4,5 Pexidartinib carries a boxed warning for hepatotoxicity and is available only through a restricted Risk Evaluation and Mitigation Strategy program.4
The double-blind MANEUVER trial enrolled 94 patients with symptomatic TGCT, including at least 1 measurable lesion of 2 cm or larger, who had not received prior anti-CSF-1 or anti-CSF-1R therapy.1,6 Participants were randomly assigned 2:1 to once-daily pimicotinib 50 mg (n = 63) or placebo (n = 31) for 24 weeks.6
The week 25 objective response rate, assessed per RECIST v1.1 by reviewers blinded to treatment assignment, was 56% (95% CI, 42%-68%) with pimicotinib and 3.2% (95% CI, 0.1%-17%) with placebo, a statistically significant difference (P < .001).1,7 The labeled rate is based on a March 2025 data cutoff; the primary analysis published in The Lancet reported 54% vs 3%.6,7 By week 13, 26 of 63 patients (41.3%) had responded.2 Median duration of response was not reached; 91% of responders maintained a response for at least 6 months and 77% for at least 12 months.1,7
Pimicotinib also produced statistically significant improvements vs placebo at week 25 on measures of active range of motion of the affected joint, worst pain, and physical functioning.1,7
“The results of the phase 3 MANEUVER trial demonstrate that [pimicotinib] elicits durable tumor response with a manageable tolerability profile,” Vinod Ravi, MD, MS, MBA, of The University of Texas MD Anderson Cancer Center, a MANEUVER investigator, said in a news release.2
Pimicotinib Safety Profile and Liver Monitoring
The most common adverse reactions, each reported in more than 20% of patients, included pruritus, rash, fatigue, nausea, headache, and edema of the face, the area around the eyes, or the extremities.7 Liver function should be checked at baseline, once a month through month 3, and then quarterly through month 12. During the 24-week blinded period, 1 patient (1.6%) receiving pimicotinib stopped treatment because of an adverse event and 5 (7.9%) needed a dose reduction.2,6
Safety and effectiveness have not been established in children, and durability data are also still maturing.7 MANEUVER compared pimicotinib with placebo rather than with other CSF-1R inhibitors, and the company did not disclose pricing or a US launch date.2 Pimicotinib was previously approved in China, Canada, and Switzerland, and reviews by other Project Orbis partners are ongoing.2
References
1. FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor. FDA. Published November 16, 2026. Accessed November 20, 2026.
2. FDA approves Pimjetmi (pimicotinib) for tenosynovial giant cell tumor (TGCT). News release. EMD Serono. November 10, 2026. Accessed November 20, 2026.
3. Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88(6):688-694. doi:10.1080/17453674.2017.1361126
4. Turalio. Prescribing information. Daiichi Sankyo; 2023. Accessed November 20, 2026.
5. FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor. FDA. Published February 14, 2025. Accessed November 20, 2026.
6. Xu H, Niu X, Ravi V, et al. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10533):1072-1083. doi:10.1016/S0140-6736(25)02602-9
7. Pimjetmi. Prescribing information. EMD Serono; 2026. Accessed November 20, 2026.
Related to this article








